Label-retaining liver cancer cells are relatively resistant to sorafenib

OBJECTIVE: The standard therapy for advanced hepatocellular carcinoma (HCC) is sorafenib, with most patients experiencing disease progression within 6 months. Label-retaining cancer cells (LRCC) represent a novel subpopulation of cancer stem cells (CSC). The objective was to test whether LRCC are re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gut
Main Authors: Xin, Hong-Wu, Ambe, Chenwi M, Hari, Danielle M, Wiegand, Gordon W, Miller, Tyler C, Chen, Jin-Qiu, Anderson, Andrew J, Ray, Satyajit, Mullinax, John E, Koizumi, Tomotake, Langan, Russell C, Burka, Douglas, Herrmann, Michelle A, Goldsmith, Paul K, Stojadinovic, Alexander, Rudloff, Udo, Thorgeirsson, Snorri S, Avital, Itzhak
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6993136/
https://ncbi.nlm.nih.gov/pubmed/23411027
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2012-303261
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados